Drugs / Comirnaty Bivalent
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05993325 Comparator | Nov 2023 → Mar 2025 overdue | COVID-19 | Cellid Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Comirnaty Bivalent | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05993325 ↗ |
| Route | Intramuscular | “via intramuscular administration in the deltoid muscle” NCT05993325 ↗ |